New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
08:12 EDTESPREsperion Therapeutics initiates Phase 2 study of ETC-1002
Esperion Therapeutics announced dosing of the first patient in its Phase 2 clinical study of ETC-1002 in patients with hypercholesterolemia and hypertension, ETC-1002-014. The company expects to announce top-line results from the study in the second quarter of 2015. The randomized, double-blind, parallel group, multicenter ETC-1002-014 study is evaluating parallel doses of ETC-1002 in approximately 144 patients. The primary objective of the study is to assess the LDL-cholesterol lowering efficacy of ETC-1002 monotherapy versus placebo in patients with both hypercholesterolemia and hypertension who are treated for six weeks. Secondary objectives include assessing the effect of ETC-1002 on blood pressure, other lipid and cardiometabolic biomarkers and characterizing the tolerability and safety of ETC-1002.
News For ESPR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
15:00 EDTESPREsperion August calls active
Subscribe for More Information
July 28, 2015
11:21 EDTESPREsperion management to meet with JMP Securities
Subscribe for More Information
10:38 EDTESPROptions with increasing implied volatility
Subscribe for More Information
09:18 EDTESPROn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTESPREsperion to host conference call
Conference call to discuss positive top-line phase 2 results for ETC-1002 will be held on July 28 at 8 am. Webcast Link
07:40 EDTESPREsperion reports ETC-1002-014 study meets primary endpoint
Subscribe for More Information
July 27, 2015
10:45 EDTESPREsperion price target lowered to $40 from $55 at Chardan
Chardan analyst Gbola Amusa earlier today lowered his price target for Esperion Therapeutics (ESPR) to $40 saying the label for Regeneron's (REGN) Praluent label "reveals multiple negatives" for the company. The FDA has had a policy change by not approving broad use for Praluent, Amusa told investors in a research note. He adds that Esperion's ETC-1002's add-on LDL-lowering ability is "much more modest" than Praluent. The analyst says he has increased conviction in his Sell rating on Esperion.
07:40 EDTESPREsperion price target lowered to $120 from $130 at Citi
Subscribe for More Information
July 24, 2015
15:27 EDTESPREsperion likely to stay pressured until path for ETC-1002 clearer, says Barclays
Subscribe for More Information
14:44 EDTESPREsperion slides after FDA assigns indication for rival cholesterol drug
Shares of Esperion Therapeutics (ESPR), a drug company focused on LDL-cholesterol lowering therapies, are sharply lower in afternoon trading after the FDA granted approval for the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 inhibitors. WHAT'S NEW: This afternoon, the FDA announced the approval of Praluent injection, which is a PCSK9 drug marketed by Sanofi (SNY) and Regeneron (REGN). Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol, the FDA indicated. The drug, like Esperion's ETC-1002, seeks to lower patients' cholesterol. PRICE ACTION: In afternoon trading, Esperion shares are down 12% to $84.21. The stock spiked as low as $81.50 immediately after the FDA made its announcement regarding Praulent. Meanwhile, Sanofi shares are fractionally higher and Regeneron shares are halted.
14:23 EDTESPREsperion drops 14.7% to $81.69 after FDA announces approval of Praluent
Subscribe for More Information
07:38 EDTESPREsperion to host analyst/investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use